Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tiny dose of naltrexone beat cancer fatigue?

NCT ID NCT07224009

Not yet recruiting Symptom relief Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a low dose of naltrexone (LDN) can reduce fatigue in men with prostate cancer who are on hormone therapy (ADT). The study will enroll 60 participants and measure fatigue, quality of life, and safety. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
low dose naltrexone (LDN)
What this could lead to
If it works, this could offer a new way to manage fatigue in men with prostate cancer on hormone therapy, improving their quality of life.
What could go wrong
This is a small, early phase 2 trial with only 60 participants. It may not show a clear benefit, and side effects from LDN are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.